• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

利用临床试验中的获益-风险评估——BRAINS 项目方案。

Utilising benefit-risk assessments within clinical trials-a protocol for the BRAINS project.

机构信息

School of Health and Related Research, University of Sheffield, Sheffield, UK.

Centre for Health Economics and Medicines Evaluation, Bangor University, Bangor, UK.

出版信息

Trials. 2021 Jan 19;22(1):68. doi: 10.1186/s13063-021-05022-0.

DOI:10.1186/s13063-021-05022-0
PMID:33468202
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7814532/
Abstract

BACKGROUND

Depending on the treatment to be investigated, a clinical trial could be designed to assess objectives of superiority, equivalence or non-inferiority. The design of the study is affected by many different elements including the control treatment, the primary outcome and associated relationships. In some studies, there could be more than one outcome of interest. In these situations, benefit-risk methodologies could be used to assess the outcomes simultaneously and consider the trade-off between the benefits against the risks of a treatment. Benefit-risk is used within the regulatory industry but seldom included within publicly funded clinical trials within the UK. This project aims to gain an expert consensus on how to select the appropriate trial design (e.g. superiority) and when to consider including benefit-risk methods.

METHODS

The project will consist of four work packages: 1. A web-based survey to elicit current experiences and opinions, 2. A rapid literature review to assess any current recommendations, 3. A two-day consensus workshop to gain agreement on the recommendations, and 4. Production of a guidance document.

DISCUSSION

The aim of the project is to provide a guideline for clinical researchers, grant funding bodies and reviewers for grant bodies for how to select the most appropriate trial design and when it is appropriate to consider using benefit-risk methods. The focus of the guideline will be on publicly funded trials however, the vision is that the work will be applicable across research settings and we will connect with other organisations and committees as appropriate.

摘要

背景

根据待研究的治疗方法,临床试验可以设计为评估优越性、等效性或非劣效性的目标。研究设计受到许多不同因素的影响,包括对照治疗、主要结局和相关关系。在某些研究中,可能有多个感兴趣的结局。在这些情况下,可以使用获益-风险方法来同时评估结局,并考虑治疗的获益与风险之间的权衡。获益-风险在监管行业中使用,但在英国,很少在公共资助的临床试验中包含。该项目旨在就如何选择适当的试验设计(例如优越性)以及何时考虑纳入获益-风险方法达成专家共识。

方法

该项目将包括四个工作包:1. 基于网络的调查,以征求当前的经验和意见;2. 快速文献综述,以评估任何现有建议;3. 为期两天的共识研讨会,以就建议达成一致;4. 编写指南文件。

讨论

该项目的目的是为临床研究人员、资助机构和资助机构的评审人员提供如何选择最合适的试验设计以及何时考虑使用获益-风险方法的指南。该指南的重点将是公共资助的试验,但我们的愿景是该工作将适用于所有研究环境,并将与其他组织和委员会进行适当的联系。

相似文献

1
Utilising benefit-risk assessments within clinical trials-a protocol for the BRAINS project.利用临床试验中的获益-风险评估——BRAINS 项目方案。
Trials. 2021 Jan 19;22(1):68. doi: 10.1186/s13063-021-05022-0.
2
Appropriate design and reporting of superiority, equivalence and non-inferiority clinical trials incorporating a benefit-risk assessment: the BRAINS study including expert workshop.纳入获益-风险评估的优效性、等效性和非劣效性临床试验的恰当设计和报告:包含专家研讨会的 BRAINS 研究。
Health Technol Assess. 2023 Oct;27(20):1-58. doi: 10.3310/BHQZ7691.
3
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
4
The future of Cochrane Neonatal.考克兰新生儿协作网的未来。
Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12.
5
Reducing bias in trials from reactions to measurement: the MERIT study including developmental work and expert workshop.减少试验中因反应而产生的偏差:MERIT 研究包括开发工作和专家研讨会。
Health Technol Assess. 2021 Sep;25(55):1-72. doi: 10.3310/hta25550.
6
Patch augmentation surgery for rotator cuff repair: the PARCS mixed-methods feasibility study.肩袖修复的补片增强手术:PARCS 混合方法可行性研究。
Health Technol Assess. 2021 Feb;25(13):1-138. doi: 10.3310/hta25130.
7
Different corticosteroid induction regimens in children and young people with juvenile idiopathic arthritis: the SIRJIA mixed-methods feasibility study.不同皮质类固醇诱导方案在儿童和青少年幼年特发性关节炎中的应用:SIRJIA 混合方法可行性研究。
Health Technol Assess. 2020 Jul;24(36):1-152. doi: 10.3310/hta24360.
8
Assessing methods to specify the target difference for a randomised controlled trial: DELTA (Difference ELicitation in TriAls) review.评估指定随机对照试验目标差值的方法:DELTA(试验中差值确定)综述。
Health Technol Assess. 2014 May;18(28):v-vi, 1-175. doi: 10.3310/hta18280.
9
Practical help for specifying the target difference in sample size calculations for RCTs: the DELTA five-stage study, including a workshop.RCT 样本量计算中目标差值指定的实用帮助:DELTA 五阶段研究,包括研讨会。
Health Technol Assess. 2019 Oct;23(60):1-88. doi: 10.3310/hta23600.
10
Lamotrigine versus levetiracetam or zonisamide for focal epilepsy and valproate versus levetiracetam for generalised and unclassified epilepsy: two SANAD II non-inferiority RCTs.拉莫三嗪对比左乙拉西坦或唑尼沙胺治疗局灶性癫痫,丙戊酸钠对比左乙拉西坦治疗全面性和未分类癫痫:两项 SANAD II 非劣效性 RCT 研究。
Health Technol Assess. 2021 Dec;25(75):1-134. doi: 10.3310/hta25750.

本文引用的文献

1
Development process of a consensus-driven CONSORT extension for randomised trials using an adaptive design.基于适应性设计的共识驱动 CONSORT 扩展随机试验的制定过程。
BMC Med. 2018 Nov 16;16(1):210. doi: 10.1186/s12916-018-1196-2.
2
Reviewing the research methods literature: principles and strategies illustrated by a systematic overview of sampling in qualitative research.回顾研究方法文献:以定性研究抽样的系统概述为例阐述的原则与策略
Syst Rev. 2016 Oct 11;5(1):172. doi: 10.1186/s13643-016-0343-0.
3
Patient-Focused Benefit-Risk Analysis to Inform Regulatory Decisions: The European Union Perspective.以患者为中心的获益-风险分析为监管决策提供信息:欧盟视角
Value Health. 2016 Sep-Oct;19(6):734-740. doi: 10.1016/j.jval.2016.04.006. Epub 2016 Sep 9.
4
Is quantitative benefit-risk modelling of drugs desirable or possible?药物的定量效益-风险建模是否可取或可行?
Drug Discov Today Technol. 2011 Spring;8(1):e1-e42. doi: 10.1016/j.ddtec.2011.03.001.
5
Through the looking glass: understanding non-inferiority.透过玻璃看:理解非劣效性。
Trials. 2011 May 3;12:106. doi: 10.1186/1745-6215-12-106.
6
Regulatory benefit-risk assessment and comparative effectiveness research: strangers, bedfellows or strange bedfellows?监管的获益-风险评估和比较效果研究:陌生人、同床异梦还是貌合神离?
Pharmacoeconomics. 2010;28(10):855-65. doi: 10.2165/11538640-000000000-00000.
7
Superiority, equivalence, and non-inferiority trials.优效性、等效性和非劣效性试验。
Bull NYU Hosp Jt Dis. 2008;66(2):150-4.
8
Current assessment of risk-benefit by regulators: is it time to introduce decision analyses?监管机构当前对风险效益的评估:是时候引入决策分析了吗?
Clin Pharmacol Ther. 2007 Aug;82(2):123-7. doi: 10.1038/sj.clpt.6100240.
9
Use of information-seeking strategies for developing systematic reviews and engaging in evidence-based practice: the application of traditional and comprehensive Pearl Growing. A review.运用信息检索策略开展系统评价并参与循证实践:传统与全面的珍珠生长法应用。综述
Int J Lang Commun Disord. 2006 Sep-Oct;41(5):567-82. doi: 10.1080/13682820600742190.
10
Three options for citation tracking: Google Scholar, Scopus and Web of Science.文献引用追踪的三种选择:谷歌学术、Scopus和科学网。
Biomed Digit Libr. 2006 Jun 29;3:7. doi: 10.1186/1742-5581-3-7.